News

BlogsPosts
Press Release

RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial

VANCOUVER, British Columbia & SAN RAFAEL, Calif.–(BUSINESS WIRE)–MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, and RepliCel Life Sciences, Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel”), a regenerative medicine company, today announced that RepliCel has joined MedCision’s ThawSTAR® Early Adopter Program, a novel program that helps companies and investigators de-risk thawing of cell therapies in early stage clinical trials through to commercialization and point-of-care. Each participant will receive a ThawSTAR® System on loan that is custom engineered for their unique cell therapy product.

Click here to view the full press release 

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.